Table 5.

Laboratory variables and weight parameters at baseline and after 8 weeks of maximally tolerated dose of carvedilol among 25 participants with intradialytic hypertension

Baseline (n=25)Study End (n=25)Mean Change from Baseline to Study EndP Value
Albumin (g/dl)3.8 (±0.55)3.8 (±0.35)−0.01 (±0.30)0.8
High-sensitivity C-reactive protein (mg/L)5.2 (1.5, 11.6)3.3 (1.5, 8.6)−0.1 (−7.5, 0.7)0.6
Hemoglobin (g/dl)12.3 (±1.1)12.2 (±1.0)−0.16 (±1.5)0.6
Serum sodium (mEq/L)135.8 (±3.7)136.1 (±3.5)−0.2 (±2.6)0.7
Total cholesterol (mg/dl)133.8 (±23.1)131.1 (±25.8)−2.8 (±16.2)0.4
LDL cholesterol (mg/dl)65.6 (±23.4)62.4 (±24.0)−3.2 (±17.2)0.4
HDL cholesterol (mg/dl)43.5 (±14.0)44.4 (±13.1)0.9 (±9.1)0.6
Target dry weight, 2-wk average (kg)81.7 (±20.0)81.6 (±20.8)−0.2 (±3.1)0.8
Intradialytic weight loss, 2-wk average (kg)2.8 (±1.0)3.0 (±1.2)−0.2 (±1.0)0.3
  • Values are reported as mean ± SD or medians and 25th to 75th interquartile ranges. P value determined from paired t tests or nonparametric signed rank tests.